Singapore, Nov. 5 -- Minghui Pharmaceutical and ASKA Pharmaceutical have entered into an exclusive license agreement for the development and commercialisation of MHB018A in Japan.

MHB018A is a novel, subcutaneously administered antibody targeting insulin-like growth factor 1 receptor (IGF-1R) for the treatment of thyroid eye disease (TED). Under the agreement, ASKA will receive exclusive rights to develop, seek regulatory approval for, and commercialise MHB018A in Japan. Minghui will retain all rights to MHB018A outside Japan and continue to lead its global development.

MHB018A has demonstrated potential best-in-class efficacy and a favorable safety profile in TED. Phase 2 data presented orally at ENDO 2026 showed robust improvements ac...